title: Response to Comment on Stegman et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care 2014;37:3114-3120.
authors.affiliation: Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.
authors.forename: Brian
authors.initials: B
authors.lastname: Stegman
authors.affiliation: C5Research, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.
authors.forename: Rishi
authors.initials: R
authors.lastname: Puri
authors.affiliation: C5Research, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.
authors.forename: Mingyuan
authors.initials: M
authors.lastname: Shao
authors.affiliation: South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia stephen.nicholls@sahmri.com.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Nicholls
mesh_terms: D000069059:Atorvastatin; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D058226:Plaque, Atherosclerotic / Q000188:drug therapy*; D011743:Pyrimidines / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D005464:Fluorobenzenes; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin